The data from the early-stage obesity study of amycretin is a short-term win for Novo Nordisk amid other factors that weigh ...

One of the hottest growth areas in the healthcare landscape these days is the obesity drug market because of a class of drugs ...

A 60-day supply is considered the benchmark for healthy inventory. Most brands had inventory levels above that 75-day average, with nine brands holding more than 100 days worth of cars at the end ...

The deal is expected to close in the second quarter of 2025. This is the company’s second acquisition in 60 days. As of September 30, 2024, the company’s cash balance stood at $0.266 million.

Lilly will also conduct a conference call that day with the investment community ... Launched in 2022, the collaboration aims to deliver a sustainable supply of high-quality, affordable human ...

Clothing brands are among the businesses benefiting from the GLP-1 boom as users treat their slimmer selves Tori Allen says she's thrilled to have lost 80 pounds since she went on Wegovy ...

Where To Watch Every Winter 2025 Anime Series Winter 2025 Anime Lineup: Crunchyroll, HIDIVE, Netflix, & More Crunchyroll Has Just Revealed Its Winter 2025 Anime Lineup Solo Leveling Season 2 ...

a hazy electronic tune which recalls the halcyon days of early 2010s dance musc. But the song's journey to Official Charts glory - it's so far peaked at Number 5 and has spent a total of seven ...

Subho Moulik, CEO of Appreciate, explains the increased interest of Indian investors in US markets, emphasizing ...

Wegovy is the first-to-market in a new class of highly effective weight-loss drugs. But analysts say that Novo’s supply constraints could allow rival Eli Lilly to get ahead, when it launches its ...

Novo Nordisk said that the launch of Wegovy had “unlocked” the obesity market, despite well-documented supply constraints, but that it is now expanding its focus beyond weight loss to ...